Our products enjoy good reputation both at home and abroad. Our trade partners are around the world, mainly in America,Europe,Australia,South East Asia ,Middle East and South Africa. In order to serve customers well, the company has established special technical department and after-sale service department. We will make careful reply if you get any question.

The company with all the employees will constantly purse excellent quality, perfect brand and our image, and adheres to our spirit of honesty, diligence, seeking truth and progress and insists on business philosophy of quality as life and service as soul. We will satisfy market demands by top products and better service, and will welcome market challenge forever.

Glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) double agonist survodutide(BI 456906) has been recognized as breakthrough therapy by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). It is intended for the treatment of metabolic dysfunction-related steatohepatitis (MASH). Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist with a unique mechanism of action. The glucagon receptor agonist component of Survodutide increases energy expenditure and directly affects the liver, helping to improve liver fibrosis. The GLP-1 agonist group can effectively reduce appetite and increase satiety at the same time.